Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety.
The INTERCEPT Blood System is designed to inactivate blood-borne
pathogens in donated blood components intended for transfusion.
Cerus currently markets the INTERCEPT Blood System for both
platelets and plasma in Europe and the Middle East.
The company is also pursuing regulatory approvals in the United
States and other countries. The INTERCEPT red blood cell system is
currently in clinical development.